Phase 3
Daiichi Sankyo Company Limited announced that the primary endpoint has been achieved in the Japan phase 3 clinical trial (ELDERCARE AF Study) for the anticoagulant, edoxaban, in elderly patients with non─valvular atrial fibrillation and high bleeding risk.